From March 12 to 15, 2024, the 14th World Antibody-Drug Conjugate Conference (World ADC) was held in London, UK. Dr. Guitao Wang,...
On October 18, 2023, Dr. Robert Huang, Founder, Chairman, and CEO of Coherent Biopharma, unveiled the latest clinical data on the company's leading pipeline product, CBP-1008, at the 14th World ADC Conference.
Coherent Biopharma announced today that their proprietary second-generation dual-ligand conjugate drug, CBP-1019, has received Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) on …
Coherent Biopharma announced that clinical data will be presented in the form of a poster at the 2023 European Society for Medical...
CBP-1018 is the first dual-ligand conjugate drug targeting PSMA and FRα developed on Coherent Biopharma (CBP)’s Bi-XDC technolo...
March 13th-16th，2023, London｜Invited by the Annual World ADC committee, Dr. Robert HUANG, the Founder and CEO of Coherent Biopharma Group attended the 13th Annual World ADC London and delivering a speech…